Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study capitalizes on the emerging technology of 19F MRI, using conventional 'thermally' polarized perfluorinated gas (perfluoropropane, or PFP) mixed with oxygen and studied with magnetic resonance imaging (MRI) to visualize ventilation. This technique has not been studied in children.
Children and adolescents (6-17 years old) with cystic fibrosis (CF) who have normal spirometry will undergo 19F MRI with the inhalation of an inert contrast gas to study ventilation. Comparisons will be made to a cohort of healthy children (6-17 years old) who will perform the same measures. The primary outcome measure is the feasibility of conducting these studies in the pediatric population. Parallel performance of multiple breath nitrogen washout (MBW) and spirometry will be used to compare the sensitivity of these outcomes to the presence of mild lung disease in these children. Finally, the investigators will compare data obtained during standard breath holds with a novel "free-breathing" technique that will eliminate the need for breath holds during MRI acquisition.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Healthy volunteers: with any history of chronic lung disease (i.e. asthma)
Active or former smoker with less than 1 year of quitting
Unable to undergo an MRI of the lungs and chest because of contraindications, including:
Unable to tolerate the inhalation of the gas mixture
Facial hair preventing a tight fit of the mask used in the study
Pregnancy
Changes in medication that may affect CF lung disease or lung function in the past 28 days, including experimental therapies
15 participants in 2 patient groups
Loading...
Central trial contact
Jennifer L Goralski, MD; Caroline Flowers, BS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal